Wednesday, December 15, 2010 (Last Updated: 12/16/2010)
WEDNESDAY, Dec. 15 (HealthDay News) -- The addition of ipilimumab (IPI) to paclitaxel/carboplatin (P/C) appears to result in superior progression-free survival in patients with stage IIIb/IV non-small-cell lung cancer (NSCLC) compared with P/C alone, according to research presented at the 2010 Chicago Multidisciplinary Symposium in Thoracic Oncology, held from Dec. 9 to 11.
Thomas J. Lynch, M.D., of the Yale Cancer Center and Smilow Cancer Hospital in New Haven, Conn., and colleagues randomized 204 patients to either IPI plus a concurrent schedule (CON) of P/C, IPI plus a phased schedule (PHA) of P/C, or P/C alone, to determine whether the addition of IPI would increase overall survival and progression-free survival in patients with stage IIIb/IV NSCLC.
The researchers found that the addition of IPI to P/C with both schedules improved the duration of progression-free survival rates compared with P/C alone. The PHA schedule had an edge over the CON schedule in terms of efficacy. The addition of IPI did not increase P/C-related toxicity.
"Phase III and IV lung cancers do not often see positive end results, so there is a lot of room to improve treatments for this disease. Ipilimumab is one of the few immunotherapies that have shown positive results in treating lung cancers, and if adding this to standard treatments can improve survival, then it is worth further trials," Lynch said in a statement.
Several authors disclosed financial relationships with pharmaceutical companies.
Hematology & Oncology
Copyright © 2010 HealthDay. All rights reserved.